Keyphrases
Antitumor Therapy
100%
Complementary Mechanism
100%
Therapy Efficacy
100%
Oncolytic Virus
100%
Microtubule-targeting Agents
100%
Acquired Resistance
28%
Cancer Cells
28%
Non-cell Autonomous
28%
Clinical Trials
14%
Molecular Mechanism
14%
Main Components
14%
Tumor
14%
In Cancer
14%
Malignancy
14%
Cell-to-cell
14%
Therapeutic Modalities
14%
Clinical Application
14%
Monotherapy
14%
Tumor Cells
14%
Cell Cycle Arrest
14%
Virus Infection
14%
Therapeutic Efficacy
14%
Standard of Care
14%
Cancer Immunotherapy
14%
Cellular Mechanisms
14%
Therapeutic Benefits
14%
Off-target Effects
14%
Microtubule Dynamics
14%
Tumor Immunity
14%
Agent-based
14%
Molecular Features
14%
Immunotherapy Agents
14%
Mitotic Cell Death
14%
Immunogenic Cell Death
14%
Medicine and Dentistry
Cancer Therapy
100%
Microtubule
100%
Oncolytic Virus
100%
Cancer Cell
28%
Infection
14%
Neoplasm
14%
Combination Therapy
14%
Clinical Trial
14%
Cell Death
14%
Weakness
14%
Monotherapy
14%
Tumor Cell
14%
Cancer
14%
Cell Cycle Arrest
14%
Virus Infection
14%
Cancer Immunotherapy
14%
Tumor Immunity
14%
Cell Cycle Checkpoint
14%
Immunogenic Cell Death
14%
Immunology and Microbiology
Microtubule
100%
Oncolytic Virus
100%
Cell Death
28%
Cancer Cell
28%
Tumor Cell
14%
Cell Cycle Arrest
14%
Viral Disease
14%
Dynamics
14%
Tumor Immunity
14%
Cancer Immunotherapy
14%
Cell Cycle Checkpoint
14%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Oncolytic Virus
100%
Malignant Neoplasm
42%
Clinical Trial
14%
Monotherapy
14%
Infection
14%
Weakness
14%
Combination Therapy
14%
Virus Infection
14%
Immunotherapy
14%
Immunogenic Cell Death
14%